OncoMed Pharma (OMED) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts OMED Hot Sheet
Join SI Premium – FREE
OncoMed Pharma (NASDAQ: OMED) reported Q3 EPS of ($0.81), $0.04 worse than the analyst estimate of ($0.77).
For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX (SPCX) PT Raised to $230 at Goldman Sachs ahead of earnings release
- AbbVie updates 2026 earnings guidance with Q3 R&D charges
- National Bank Holdings (NBHC) PT Lowered to $43 at DA Davidson
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
